Key Takeaways
- • KKR to acquire Integer Holdings Corp., a medical device manufacturer, in an all-cash transaction valued at approximately $5.7 billion enterprise value, announced August 3, 2026.
- • Kirkland & Ellis LLP and Davis Polk & Wardwell LLP are advising on the transaction, representing major legal counsel involvement typical of large-cap private equity acquisitions.
- • The all-cash structure indicates KKR's commitment to a clean acquisition without financing contingencies, reducing execution risk for the target company shareholders.
- • This acquisition expands KKR's portfolio in the medical device sector, a healthcare subsegment characterized by recurring revenue streams and regulatory moats.
Summary
KKR announced on Monday, August 3, 2026, that it will acquire Integer Holdings Corp., a medical device company, in an all-cash transaction valued at approximately $5.7 billion in enterprise value. The transaction represents a significant add to KKR's healthcare investment portfolio and underscores continued institutional capital deployment into the medical technology sector.
The deal is being advised by two leading global law firms: Kirkland & Ellis LLP and Davis Polk & Wardwell LLP. The involvement of both firms signals the transaction's complexity and size, with each typically handling distinct aspects of large leveraged buyouts or private equity acquisitions—including financing documentation, representations and warranties, regulatory compliance, and post-close integration planning.
The all-cash structure of the acquisition eliminates financing risk and provides Integer Holdings shareholders with certainty of closing, a material consideration in transactions of this magnitude. This approach is consistent with KKR's financial flexibility and strong capital base, allowing the firm to compete aggressively for quality assets in the healthcare sector without contingent funding arrangements.
Integer Holdings operates in the medical device industry, a sector characterized by recurring revenue visibility, high barriers to entry due to regulatory requirements, and strong cash generation potential—factors that typically attract large alternative asset managers seeking durable, inflation-resilient assets. The acquisition reflects continued institutional investor appetite for consolidated healthcare-focused businesses with established market positions and technology platforms.
The deal is being advised by two leading global law firms: Kirkland & Ellis LLP and Davis Polk & Wardwell LLP. The involvement of both firms signals the transaction's complexity and size, with each typically handling distinct aspects of large leveraged buyouts or private equity acquisitions—including financing documentation, representations and warranties, regulatory compliance, and post-close integration planning.
The all-cash structure of the acquisition eliminates financing risk and provides Integer Holdings shareholders with certainty of closing, a material consideration in transactions of this magnitude. This approach is consistent with KKR's financial flexibility and strong capital base, allowing the firm to compete aggressively for quality assets in the healthcare sector without contingent funding arrangements.
Integer Holdings operates in the medical device industry, a sector characterized by recurring revenue visibility, high barriers to entry due to regulatory requirements, and strong cash generation potential—factors that typically attract large alternative asset managers seeking durable, inflation-resilient assets. The acquisition reflects continued institutional investor appetite for consolidated healthcare-focused businesses with established market positions and technology platforms.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.